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Abstract
Background
In resource-limited settings, routine monitoring of renal function during antiretroviral therapy
(ART) has not been recommended. However, concerns for tenofovir disoproxil fumarate
(TDF)-related nephrotoxicity persist with increased use.
Methods
We investigated serum creatinine (S-Cr) monitoring rates before and during ART and the
incidence and prevalence of renal dysfunction after starting TDF by using data from a
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regional cohort of HIV-infected individuals in the Asia-Pacific. Time to renal dysfunction
was defined as time from TDF initiation to the decline in estimated glomerular filtration rate
(eGFR) to <60 ml/min/1.73m2 with >30% reduction from baseline using the Chronic Kidney
Disease Epidemiology Collaboration (CKD-EPI) equation or the decision to stop TDF for
reported TDF-nephrotoxicity. Predictors of S-Cr monitoring rates were assessed by Pois-
son regression and risk factors for developing renal dysfunction were assessed by Cox
regression.
Results
Among 2,425 patients who received TDF, S-Cr monitoring rates increased from 1.01 to 1.84
per person per year after starting TDF (incidence rate ratio 1.68, 95%CI 1.62–1.74, p
<0.001). Renal dysfunction on TDF occurred in 103 patients over 5,368 person-years of
TDF use (4.2%; incidence 1.75 per 100 person-years). Risk factors for developing renal
dysfunction included older age (>50 vs.30, hazard ratio [HR] 5.39, 95%CI 2.52–11.50,
p <0.001; and using PI-based regimen (HR 1.93, 95%CI 1.22–3.07, p = 0.005). Having an
eGFR prior to TDF (pre-TDF eGFR) of60 ml/min/1.73m2 showed a protective effect (HR
0.38, 95%CI, 0.17–0.85, p = 0.018).
Conclusions
Renal dysfunction on commencing TDF use was not common, however, older age, lower
baseline eGFR and PI-based ART were associated with higher risk of renal dysfunction dur-
ing TDF use in adult HIV-infected individuals in the Asia-Pacific region.
Introduction
The widespread use of antiretroviral therapy (ART) has brought a marked decline in mortality
and morbidity of HIV-infected individuals, but concerns have grown regarding the emergence
of other chronic diseases associated with extended life expectancies coupled with the long-term
effects of HIV disease and its treatment. One of the serious non-AIDS conditions which have
increased mortality in the post-ART era is chronic kidney disease (CKD) [1, 2]. Although rap-
idly progressive HIV-associated nephropathy (HIVAN) has less frequently been seen, nephro-
toxicity due to some antiretrovirals (ARV), including tenofovir disoproxil fumarate (TDF), has
been well documented [3–7].
TDF is rapidly becoming one of the most widely used ARVs in the world [8–10]. Although
the mechanism of TDF-related nephrotoxicity has not been fully elucidated, it presents with
decreased glomerular filtration rate (GFR) and proximal tubular dysfunction [11]. TDF neph-
rotoxicity may be partly irreversible; therefore early detection of renal dysfunction is a key ele-
ment of the clinical management [12, 13]. The HIV Medicine Association of the Infectious
Diseases Society of America (IDSA) recommends twice yearly monitoring of estimated GFR
(eGFR), serum phosphate and urinalysis while receiving TDF [7, 14].
On the other hand, frequent laboratory monitoring of serum creatinine (S-Cr) may not be
practical in resource-limited settings, and the World Health Organization (WHO) has yet to
recommend routine S-Cr testing before and during ART [10]. As TDF use has expanded in
resource-limited settings, there are limited data on how often renal function is being monitored
and the extent of associated nephrotoxicity being observed [10].
Renal Function during TDF Use in the Asia-Pacific
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In this analysis, we evaluated the frequencies of S-Cr measurement before and during TDF
use, and the incidence and factors of renal dysfunction while on TDF in a large prospective
cohort in the Asia-Pacific region: the TREAT Asia HIV Observational Database (TAHOD)
[15].
Methods
Two analyses were conducted based on data collected in TAHOD [15]. Briefly, TAHOD is an
observational study of patients with HIV involving 22 adult treatment centers in 12 countries
and territories of varying income levels in Asia. The study was established in 2003 and aims to
assess HIV disease natural history in treated and untreated patients in the region. Retrospective
and prospective data is collected at each site. Data is transferred to the data management center
at the Kirby Institute, Sydney, Australia, twice annually in March and September.
Analysis (i): To determine frequencies of S-Cr monitoring before and
during TDF use
In this analysis, we included TAHOD patients who had ever received TDF as part of an ART
regimen consisting of at least three ARVs. Factors associated with rates of S-Cr monitoring
(S-Cr rates) were analyzed using a Poisson regression model with random effects on the patient
to account for repeated measurements of S-Cr in individual patients. Analysis time began from
ART initiation and was censored when TDF was discontinued for more than seven days, at
death or the last follow-up date, whichever occurred first. Patients who re-started TDF after
seven days did not re-enter the analysis risk set. Time-fixed covariates included in the model
were age, weight, CD4 count, viral load (VL) and hepatitis B/C co-infection at ART initiation,
mode of HIV exposure, initial ART regimen, prior AIDS defining illnesses (Centers for Disease
Control and Prevention [CDC] Category C), pre-ART eGFR, andWorld Bank country income
level [16]. Time-updated covariates were TDF use, indinavir (IDV) use, high fasting glucose
level (FGL) and high blood pressure. High FGL was defined as a single FGL7 mmol/L or
126 mg/dL. High blood pressure was defined as a single systolic>140 mmHg or diastolic
>90 mmHg measurement.
Trends in crude rates of S-Cr testing for each year on TDF were also explored using Poisson
regression with follow-up time beginning from TDF initiation.
Analysis (ii): To determine factors associated with time to renal
dysfunction on TDF
Patient selection followed the same criteria as per analysis (i). TDF-related renal toxicity was
defined as having eGFR reduction of at least 30% of the baseline value and<60 ml/min/
1.73m2, or having ART stopped for reported renal toxicity. The eGFR value used to calculate
the percentage decline was the value within six months prior to and closest to the date of TDF
initiation. In order to include patients without pre-TDF S-Cr assessment, the first S-Cr after
TDF initiation was used as the initial eGFR. The eGFR was calculated according to the Chronic
Kidney Disease Epidemiology Collaboration (CKD-EPI) equation [17]. The analysis risk time
began at TDF initiation rather than from the time of overall ART initiation. To account for
censored observations, time to renal dysfunction was analyzed using a Cox regression model
and stratified by site. Patients were censored at TDF discontinuation of more than seven days,
the last follow-up date or death. Covariates included in the model were age at TDF initiation,
sex, mode of HIV exposure, pre-TDF weight, pre-TDF eGFR, pre-TDF VL and CD4 count,
TDF combination, prior ART exposure, hepatitis B/C co-infection, prior AIDS illnesses, S-Cr
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assessment in the previous six months, indinavir use, high FGL, high blood pressure, and ART
adherence. S-Cr assessment in the previous six months was coded as a time-updated binary
variable where “Yes” referred to having at least one S-Cr assessment in the previous 6-month
interval, and “No”meant having no assessment in that time period. To construct this covariate,
time was calculated as discrete 6-monthly intervals from TDF initiation (e.g., first six months,
second six months). Therefore, if a patient’s total follow-up time were currently seven months
from TDF initiation, the S-Cr assessment covariate for this patient would refer to the time
period between month one to six. If the follow-up time were 11 months, the S-Cr covariate
would still refer to month one to six. As such, the S-Cr covariate did not vary continuously, but
discretely according to the time interval from TDF initiation. ART adherence was collected
from the self-reported visual analogue scale (VAS) [18], and coded as<95%,95% or missing.
All regression models were fitted using backward stepwise selection process. Variables sig-
nificant in the univariate analysis at Wald’s test p<0.10 were chosen for inclusion in the multi-
variate model. Variables significant at p<0.05 were considered statistically significant in the
final multivariate model. All data management and statistical analyses were performed using
SAS software version 9.3 (SAS Institute Inc., Cary, NC, USA) and STATA software version
12.1 (STATA Corp., College Station, TX, USA).
Ethics approval for the TAHOD study design, methods, and consent procedures, was
granted by the University of New South Wales, Human Research Ethics Committee. Site-spe-
cific study governance was granted by site-relevant institutional review boards. Written
informed consent was not sought in TAHOD unless required by a site’s local institutional
review board. Informed consent was waived at some sites as information is collected via an
anonymous case report form. All study procedures were developed in accordance with the
revised Helsinki Declaration.
Results
The analysis included a total of 2,425 patients from Cambodia, China (including Hong Kong
SAR), India, Indonesia, Japan, Malaysia, the Philippines, Singapore, South Korea, Taiwan,
Thailand and Vietnam. Patients initiated ART between 1996 and 2013 and contributed to
13,019 person years on ART and 5,368 years on TDF use. Table 1 shows patient characteristics
of these patients before ART initiation, and the number of patients with2 average S-Cr
assessments per year. Of the 2,425 patients, 69% were male with heterosexual exposure as the
reported exposure category for HIV infection. The median age was 35 years (interquartile
range [IQR]: 30–42), median VL was 100,000 copies/mL (IQR: 34,388–270,000) and median
CD4 count was 114 cells/μL (IQR: 39–214). Initial ART combinations consisted mainly of
nucleoside reverse transcriptase inhibitors (NRTI), plus non-NRTIs (NNRTI; 83%). More than
60% had no hepatitis B or C co-infections or prior AIDS illnesses. Six hundred and twenty
seven of the 2,425 patients (26%) had2 S-Cr assessments per year. The proportion was rela-
tively higher after TDF initiation than prior to TDF use (38% vs. 18%, p<0.001). These charac-
teristics are also reported by country in S1 Table.
Analysis (i): To determine rates of S-Cr monitoring before and during
TDF use
Table 2 shows results from a Poisson-random effects model for factors associated with S-Cr
monitoring after ART initiation. The overall crude rate was 1.41 per person-year (/PY). The
rate while receiving TDF was 1.89/PY, which was relatively higher than the rate before receiv-
ing TDF of 1.01/PY (p<0.001). The maximum follow-up time from ART initiation to the cen-
soring date was 16.9 years, and the maximum time from TDF initiation was 9.6 years. The
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Table 1. Baseline demographics of patients who have ever received TDF.
Total (%) aNumber with average S-Cr assessments2 per year b(%)
2,425 (100) 627 (25.9)
Age at ART initiation (years) median 35, IQR (30–42)
30 680 (28.0) 151 (22.2)
31–40 1,043 (43.0) 256 (24.5)
41–50 499 (20.6) 149 (29.9)
>50 203 (8.4) 71 (35.0)
Sex
Male 1,668 (68.8) 498 (29.9)
Female 757 (31.2) 129 (17.0)
Mode of HIV Exposure
Heterosexual contact 1,671 (68.9) 317 (19.0)
Homosexual contact 452 (18.6) 203 (44.9)
Injecting drug use 164 (6.8) 39 (23.8)
Other/unknown 138 (5.7) 68 (49.3)
Pre-ART weight (kg) median = 54.9, IQR (48–63.8)
55 823 (33.9) 162 (19.7)
>55 732 (30.2) 244 (33.3)
Missing 870 (35.9) 221 (25.4)
Pre-ART viral load (copies/mL) median = 100,000, IQR (34,388–270,000)
100,000 599 (24.7) 217 (36.2)
>100,000 586 (24.2) 225 (38.4)
Missing 1,240 (51.1) 185 (14.9)
Pre-ART CD4 (cells/μL) median = 114, IQR (39–214)
50 634 (26.1) 129 (20.3)
51–100 311 (12.8) 66 (21.2)
101–200 519 (21.4) 155 (29.9)
>200 561 (23.1) 204 (36.4)
Missing 400 (16.5) 73 (18.3)
Initial ART Regimen
NRTI+NNRTI 2,014 (83.1) 402 (20.0)
NRTI+PI 365 (15.1) 211 (57.8)
Other 46 (1.9) 14 (30.4)
Hepatitis B co-infection
Negative 1,593 (65.7) 468 (29.4)
Positive 334 (13.8) 102 (30.5)
Not tested 498 (20.5) 57 (11.4)
Hepatitis C co-infection
Negative 1,547 (63.8) 472 (30.5)
Positive 263 (10.8) 58 (22.1)
Not tested 615 (25.4) 97 (15.8)
Previous AIDS
No 1,470 (60.6) 403 (27.4)
Yes 955 (39.4) 224 (23.5)
Country Income Level
Low + Lower Middle 898 (37.0) 137 (15.3)
Upper Middle 1,196 (49.3) 288 (24.1)
High 331 (13.6) 202 (61.0)
(Continued)
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multivariate model showed that after adjusting for significant predictors, the incidence rate
ratio (IRR) for S-Cr testing during TDF compared to prior to TDF use was 1.68 (95% confi-
dence interval (CI) 1.62–1.74, p<0.001). Other factors associated with higher S-Cr monitoring
frequencies were injecting drug use (IDU) compared to heterosexual mode of HIV exposure
(IRR 1.22, 95% CI 1.08–1.38; p = 0.002), baseline VL>100,000 compared to100,000 copies/
mL (IRR 1.27, 95% CI 1.16–1.38; p<0.001), PI-based initial regimen compared to NNRTI-
based regimen (IRR 1.27, 95% CI 1.16–1.38; p<0.001), World Bank upper middle-income
countries (IRR 1.15, 95% CI 1.06–1.24; p<0.001) and high-income countries (IRR 2.05, 95%
CI 1.83–2.30; p<0.001) compared to low- and lower middle-income countries, and high FGL
compared to FGL below 7 mmol/L or 126 mg/dL (IRR 1.15, 95% CI 1.05–1.25; p = 0.002). Hav-
ing eGFR prior to ART60 ml/min/1.73m2 compared to<60 ml/mim/1.73m2 (IRR 0.72, 95%
CI (0.54, 0.95); p = 0.019).
Crude rates of S-Cr monitoring for each year on TDF are shown in Table 3. The highest rate
of 2.06/PYs (95%CI 2.01–2.11) was observed in the first year on TDF. The rates were shown to
have a decreasing trend (p<0.001) as time on TDF increased; however, rates remained above
1.00/PY across all years, suggesting that in this cohort S-Cr was measured, on average, at least
annually while receiving TDF.
Analysis (ii): To determine factors associated with time to renal
dysfunction on TDF
There were 649/2425 patients (27%) whose first S-Cr measurement used to estimate the base-
line GFR occurred after TDF initiation. The median delay between TDF initiation and first
S-Cr measurement in this subgroup of patients was 5 months (IQR: 1.4–13 months). The total
number of patients with renal dysfunction during TDF use was 103/2425 (4.2%) and the crude
toxicity rate was 1.75 per 100PYs. During a median time of follow-up of 2.07 (IQR 1.00–3.56
years, 89 met the eGFR criteria of a decline to 60 ml/min/1.73m2 with at least 30% reduction
from the baseline. The remaining 14 patients were classified according to reported reasons for
ARV discontinuation. Factors associated with time to renal dysfunction are shown in Table 4.
The multivariate model showed that the older age group of>50 years (hazard ratio [HR] 5.39,
95%CI 2.52–11.50, p<0.001) had higher risk of developing renal dysfunction compared to
Table 1. (Continued)
Total (%) aNumber with average S-Cr assessments2 per year b(%)
2,425 (100) 627 (25.9)
Pre-ART eGFR (ml/min per 1.73 m2)
<60 25 (1.0) 15 (60.0)
60 1166 (48.1) 470 (40.3)
Missing 1234 (50.9) 142 (11.5)
cTDF use
Prior to TDF initiation N/A 293 (17.9)
After TDF initiation N/A 929 (38.3)
Note:
a
—Average calculated by the total number of serum creatinine assessments divided by the total follow-up time for each patient.
b
—Proportion of patients having two serum creatinine assessments divided by the total number of patients in the same category.
c
—Time-updated variable. The same patient can be counted in both categories.
TDF, tenofovir disoproxil fumarate; S-Cr, serum creatinine; ART, antiretroviral therapy; IQR, interquartile range; NRTI, nucleos(t)ide reverse transcriptase
inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor
doi:10.1371/journal.pone.0161562.t001
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Table 2. Factors associated with rates of serum creatinine monitoring after ART initiation.
Univariate Multivariate
Person-
years
Number S-Cr
assessments
cCrude
rate
95% CI IRR 95% CI p IRR 95% CI p
Age at ART initiation (years) <0.001
30 3769.9 4846 1.29 (1.25, 1.32) 1
31–40 5877.8 8052 1.37 (1.34, 1.40) 1.06 (0.97, 1.15) 0.231
41–50 2420.6 3903 1.61 (1.56, 1.66) 1.29 (1.16, 1.44) <0.001
51+ 951.0 1608 1.69 (1.61, 1.78) 1.24 (1.07, 1.43) 0.003
Sex
Male 8719.6 12918 1.48 (1.46, 1.51) 1
Female 4299.7 5491 1.28 (1.24, 1.31) 0.82 (0.76, 0.89) <0.001
Mode of HIV Exposure <0.001 0.009
Heterosexual contact 9598.4 12463 1.30 (1.28, 1.32) 1 1
Homosexual contact 2077.0 3675 1.77 (1.71, 1.83) 1.52 (1.38, 1.67) <0.001 0.95 (0.87, 1.04) 0.304
Injecting drug use 657.5 1004 1.53 (1.44, 1.62) 1.18 (1.02, 1.37) 0.028 1.22 (1.08, 1.38) 0.002
Other/unknown 686.5 1267 1.85 (1.75, 1.95) 1.43 (1.23, 1.67) <0.001 1.02 (0.89, 1.16) 0.800
Pre-ART weight (kg)
>55 3227.3 5731 1.78 (1.73, 1.82) 1
55 4106.6 5662 1.38 (1.34, 1.42) 0.80 (0.73, 0.89) <0.001
Missing 5685.4 7016 1.23 (1.21, 1.26)
Pre-ART viral load (copies/
mL)
100000 2793.8 4967 1.78 (1.73, 1.83) 1 1
>100000 2614.8 5370 2.05 (2.00, 2.11) 1.22 (1.10, 1.34) <0.001 1.27 (1.16, 1.38) <0.001
Missing 7610.7 8072 1.06 (1.04, 1.08)
Pre-ART CD4 (cells/μL) 0.001
50 3318.4 4702 1.42 (1.38, 1.46) 1
51–100 1690.3 2161 1.28 (1.23, 1.33) 1.01 (0.89, 1.15) 0.848
101–200 2784.5 4356 1.56 (1.52, 1.61) 1.12 (1.01, 1.25) 0.030
>200 2427.3 4116 1.70 (1.64, 1.75) 1.21 (1.09, 1.35) <0.001
Missing 2798.8 3074 1.10 (1.06, 1.14)
Initial ART Regimen <0.001 <0.001
NRTI+NNRTI 10842.9 13985 1.29 (1.27, 1.31) 1 1
NRTI+PI 1903.6 3983 2.09 (2.03, 2.16) 2.03 (1.84, 2.24) <0.001 1.27 (1.16, 1.38) <0.001
Other 272.8 441 1.62 (1.47, 1.77) 1.18 (0.91, 1.53) 0.219 0.83 (0.67, 1.02) 0.080
Hepatitis B co-infection
Negative 8303.4 13200 1.59 (1.56, 1.62) 1
Positive 1676.6 2676 1.60 (1.54, 1.66) 0.93 (0.84, 1.04) 0.190
Not tested 3039.3 2533 0.83 (0.80, 0.87)
Hepatitis C co-infection
Negative 8389.9 13102 1.56 (1.54, 1.59) 1
Positive 1138.6 1869 1.64 (1.57, 1.72) 0.97 (0.86, 1.10) 0.657
Not tested 3490.9 3438 0.98 (0.95, 1.02)
Previous AIDS
No 7714.0 10758 1.39 (1.37, 1.42) 1
Yes 5305.3 7651 1.44 (1.41, 1.47) 1.04 (0.96, 1.12) 0.359
Country Income Level <0.001 <0.001
Low + Lower Middle 4166.7 4326 1.04 (1.01, 1.07) 1 1
Upper Middle 7078.0 10336 1.46 (1.43, 1.49) 1.39 (1.29, 1.51) <0.001 1.34 (1.24, 1.45) <0.001
(Continued)
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those30 years. Patients who took a PI-based regimen at the time of TDF initiation were
almost twice as likely to have toxicity compared to those on an NNRTI-based regimen (HR
1.93, 95%CI 1.22–3.07, p = 0.005). Those with pre-TDF eGFR60 ml/min/1.73m2 showed a
protective effect (HR 0.38, 95%CI, 0.17–0.85, p = 0.018). ART adherence and S-Cr assessment
in the previous 6-month interval were not associated with renal dysfunction.
Discussion
In this study, we evaluated the frequency of S-Cr monitoring during ART in a large cohort of
adult HIV-infected individuals in the Asia-Pacific region and described the incidence and prev-
alence of renal dysfunction after starting TDF. We found S-Cr was assessed at least once a year
during ART and more often after starting TDF. Our study also revealed that 4.2% of individu-
als experienced eGFR decline to<60 ml/min/1.73m2 with>30% reduction from baseline or
had stopped ART for reported TDF-nephrotoxicity with an incidence of 1.75/100PYs. These
data support the need for renal function monitoring for patients receiving TDF-containing
ART in resource-limited settings.
Table 2. (Continued)
Univariate Multivariate
Person-
years
Number S-Cr
assessments
cCrude
rate
95% CI IRR 95% CI p IRR 95% CI p
High 1774.7 3747 2.11 (2.04, 2.18) 2.21 (1.97, 2.48) <0.001 2.05 (1.83, 2.30) <0.001
pre-ART eGFR(ml/min per
1.73 m2)
<60 105.5 289 2.74 (2.44, 3.07) 1 1
60 4539.7 9507 2.09 (2.05, 2.14) 0.75 (0.54, 1.03) 0.071 0.72 (0.54, 0.95) 0.019
Missing 8374.1 8613 1.03 (1.01, 1.05)
dReceiving TDF
No 7025.1 7098 1.01 (0.99, 1.03) 1 1
Yes 5994.2 11311 1.89 (1.85, 1.92) 1.93 (1.86, 2.00) <0.001 1.68 (1.62, 1.74) <0.001
dReceiving IDV
No 12706.8 17945 1.41 (1.39, 1.43) 1
Yes 312.5 464 1.49 (1.36, 1.63) 0.95 (0.84, 1.07) 0.388
a,dHigh fasting glucose level
No 7566.6 13579 1.79 (1.76, 1.83) 1 1
Yes 522.2 998 1.91 (1.80, 2.03) 1.11 (1.02, 1.21) 0.021 1.15 (1.05, 1.25) 0.002
Missing 4930.5 3832 0.78 (0.75, 0.80)
b,dHigh blood pressure
No 8047.3 11923 1.48 (1.46, 1.51) 1
Yes 1429.3 2379 1.66 (1.60, 1.73) 1.08 (1.02, 1.14) 0.005
Missing 3542.7 4107 1.16 (1.12, 1.20)
Note:
a
—high fasting glucose deﬁned as7 mmol/L or126 mg/dL.
b
—High blood pressure deﬁned as systolic >140 mmHg, or diastolic >90 mmHg.
c
—Crude rate, per person-year
d
—Time-updated variables
Missing values were coded as a separate category and were excluded from test for heterogeneity.
S-Cr, serum creatinine; CI, conﬁdential interval; IRR, incident rate ratio; ART, antiretroviral therapy; NRTI, nucleos(t)ide reverse transcriptase inhibitor;
NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; TDF, tenofovir disoproxil fumarate; IDV, indinavir.
doi:10.1371/journal.pone.0161562.t002
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Previously, a study from Africa showed limited improvement of prognosis in patients
receiving regular laboratory monitoring during ART [19]. The WHO currently does not rec-
ommend baseline or routine monitoring of S-Cr during ART in resource-limited settings, in
accordance with the results of the DART trial [9]. However, S-Cr was measured regularly in
our study sites regardless of country income levels. The possible reason for such routine S-Cr
measurement is that the local ART guideline in each country recommends TDF dose reduction
when CrCl is<50 ml/min and TDF switch when CrCl is<30 ml/min. Even if S-Cr monitoring
is not routinely recommended in the guidelies, the indications to modify TDF dosage may
encourage physicians to measure S-Cr regularly. Our data provides an important aspect to the
feasibility of regular S-Cr monitoring during TDF use in the Asia-Pacific region.
We observed 1.75/100PYs incidence and 4.2% prevalence of renal dysfunction during a
median 2.07 years on TDF. The incidence and prevalence in our study were comparable to pre-
vious studies [19–23]. However, while severe renal dysfunction that requiring TDF discontinu-
ation was rare in most of those studies, 13.6% (14/103) of the patients defined as having renal
dysfunction discontinued TDF for the reason of TDF-nephrotoxicity. TDF tends to be discon-
tinued by physicians earlier than the guidelines indicate (CrCl 30 ml/min) to avoid making the
renal dysfunction irreversible and deciding to discontinue TDF may be easier if other ARV
options are available. The severity and the reversibility of renal function need to be considered
before deciding to discontinue TDF. Therefore, more information is needed to establish an
optimal indication for TDF discontinuation in order to preserve future renal function and min-
imize unnecessary ARV changes from a long-term perspective.
We found that older age (>50 years), lower pre-TDF eGFR (<60 ml/min/1.73m2) and PI-
based regimen are associated with higher risk of renal dysfunction in multivariate analysis, all
of which were compatible with previous studies and the WHO recommendations for regular
S-Cr monitoring [10,19–21,24]. The higher risk in older age and lower pre-TDF eGFR can be
explained by the fact that the CKD prevalence rises with age due to the increasing prevalence
of risk factors for CKD, such as diabetes and hypertension, and the natural decline of renal
function associated with aging [25]. For patients on PI-based regimens, the majority of them
(48%) used lopinavir-ritonavir (LPVr). Concurrent use of ritonavir and TDF could result in
accumulation of TDF and lead to higher risk for TDF-induced nephrotoxicity [24]. Since LPVr
has been widely used as the second line ART for those who failed the first NNRTI-based ART,
TDF-nephrotoxicity may be a cause of concen in that population. We did not find an increased
risk in those who had lower CD4 counts, higher plasma viral loads or lower body weight,
although those factors are reported to predict renal dysfunction during ART [19–23]. The
patients in our cohort had lower CD4 counts at ART initiation than those in resource-rich
countries and we were not able to compare the risks with a group of high baseline CD4 counts.
Since there has been a global shift toward early ART initiation at higher baseline CD4 counts,
Table 3. Crude rates of serum creatinine monitoring for each year on TDF.
Year on TDF Person-years of observation Number of S-Cr assessments Crude rate (per person-year) 95% CI
1st 3,041.02 6,260 2.06 (2.01, 2.11)
2nd 1,270.4 2,236 1.76 (1.69, 1.83)
3rd 824.6 1,445 1.75 (1.66, 1.85)
4th 515.41 781 1.52 (1.41, 1.63)
5th 220.93 361 1.63 (1.47, 1.81)
6th-10th 121.81 228 1.87 (1.64, 2.13)
TDF, tenofovir disoproxil fumarate; S-Cr, serum creatinine; CI, conﬁdential interval.
doi:10.1371/journal.pone.0161562.t003
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Table 4. Factors associated with time to renal dysfunction during TDF use.
Univariate Multivariate
Person-
years
Number of patients with
renal dysfunction
cCrude
rate
HR 95% CI p HR 95% CI p
Total 5886.6 103 1.75
Age at TDF initiation (years) <0.001
30 942.9 9 0.95 1 1
31–40 2606.6 29 1.11 1.08 (0.51, 2.31) 0.836 1.09 (0.51, 2.34) 0.815
41–50 1679.7 26 1.55 1.50 (0.69, 3.26) 0.303 1.58 (0.73, 3.44) 0.248
51+ 657.4 39 5.93 5.81 (2.75, 12.26) <0.001 5.39 (2.52, 11.50) <0.001
Sex
Male 3983.7 78 1.96 1
Female 1902.9 25 1.31 0.76 (0.47, 1.21) 0.249
Mode of HIV Exposure 0.069
Heterosexual contact 4120.9 81 1.97 1
Homosexual contact 1202.7 10 0.83 0.35 (0.15, 0.79) 0.011
Injecting drug use 291.7 4 1.37 0.75 (0.25, 2.23) 0.599
Other/unknown 271.2 8 2.95 1.10 (0.51, 2.40) 0.800
Pre-TDFWeight (kg)
55 2012.8 35 1.74 1
>55 2907.0 49 1.69 0.92 (0.59, 1.44) 0.716
Missing 966.7 19 1.97
Pre-TDF eGFR (ml/min 1.73 m2)
<60 68.5 8 11.69 1 1
60 3678.9 62 1.69 0.19 (0.09, 0.41) <0.001 0.38 (0.17, 0.85) 0.018
Missing 2139.2 33 1.54
Pre-TDF viral load (copies/mL)
<5000 1915.3 31 1.62 1
5000 2087.0 30 1.44 0.90 (0.52, 1.58) 0.718
Missing 1884.2 42 2.23
Pre-TDF CD4 (cells/μL) 0.208
50 553.0 15 2.71 1
51–100 409.2 6 1.47 0.54 (0.21, 1.41) 0.210
101–200 1012.8 16 1.58 0.52 (0.25, 1.08) 0.078
201+ 3270.0 53 1.62 0.53 (0.29, 0.98) 0.043
Missing 641.5 13 2.03
TDF combination 0.011
NNRTI 4210.9 66 1.57 1 1
PI 1490.0 34 2.28 1.99 (1.25, 3.15) 0.003 1.93 (1.22, 3.07) 0.005
Other 185.7 3 1.62 2.13 (0.64, 7.11) 0.217 2.14 (0.64, 7.20) 0.217
Prior ARV exposure
No 2154.9 24 1.11 1
Yes 3731.6 79 2.12 1.80 (1.09, 2.99) 0.022
Hepatitis B co-infection
Negative 3824.0 60 1.57 1
Positive 842.5 16 1.90 1.15 (0.65, 2.03) 0.632
Not tested 1220.0 27 2.21 1.69 (0.90, 3.19) 0.103
Hepatitis C co-infection
Negative 3806.1 57 1.50 1
(Continued)
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there may be a limitation in the generalization of our results in this context. In addition, details
of the baseline viral loads in almost half of our patients and body weight in 35% were unavail-
able, which may have affected the power to detect association with renal dysfunction risk. Our
results may be useful when we target populations who have more benefit from S-Cr monitoring
in resource-limited settings.
Limitations of our study include difficulty in capturing all renal events. Many of the study
sites are in resource-limited settings, where the national ART guidelines recommend TDF
switch by single test result, and S-Cr was measured approximately twice yearly. Thus, we were
not able to utilize secondary confirmatory testing or distinguish between acute and chronic
renal dysfunction. In addition, results of urinalysis, electrolytes or other laboratory data to
assess tubular function were not collected in TAHOD. These limitations may have affected the
classification of renal dysfunction events, which could lead to the underestimation of the renal
dysfunction in this study. Moreover, our definition of eGFR decline meant that patients who
did not have an eGFR below 60 ml/min/1.73m2 were not counted as having renal dysfunction
Table 4. (Continued)
Univariate Multivariate
Person-
years
Number of patients with
renal dysfunction
cCrude
rate
HR 95% CI p HR 95% CI p
Positive 469.1 10 2.13 1.56 (0.73, 3.32) 0.252
Not tested 1611.4 36 2.23
Previous AIDS
No 3337.6 47 1.41 1
Yes 2549.0 56 2.20 1.47 (0.98, 2.21) 0.064
dCreatinine assessment in the
previous 6 months
No 2256.2 29 1.29 1
Yes 3630.4 74 2.04 1.27 (0.78, 2.09) 0.336
a,dHigh fasting glucose level
No 937.3 16 1.71 1
Yes 62.9 3 4.77 2.63 (0.74, 9.37) 0.135
Not tested 4886.4 84 1.72
b,dHigh blood pressure
No 2097.9 33 1.57 1
Yes 412.7 8 1.94 1.15 (0.53, 2.53) 0.722
Not tested 3376.0 62 1.84
dART adherence
<95% 30.8 1 3.25 1
95% 2221.2 33 1.49 0.43 (0.06, 3.27) 0.414
Missing 3634.6 69 1.90
Note:
a
—high fasting glucose deﬁned as7 mmol/L or126 mg/dL.
b
—High blood pressure deﬁned as systolic >140 mmHg, or diastolic >90 mmHg.
c
—Crude rate, per 100 person-years.
d
—Time-updated variables.
Missing values were coded as a separate category and were excluded from test for heterogeneity.
TDF, tenofovir disoproxil fumarate; S-Cr, serum creatinine; CI, conﬁdential interval; HR, incident rate ratio; NNRTI, non-nucleoside reverse transcriptase
inhibitor; PI, protease inhibitor; ARV, antiretroviral agent; IDV, indinavir; ART, antiretroviral therapy.
doi:10.1371/journal.pone.0161562.t004
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even if the decline was at least 30%. Using this definition could lead to the underestimation of
renal dysfunction, however we believe it better relates to the need for TDF discontinuation
than the 30% reduction alone. Furthermore, it was not possible to confirm that all renal dys-
function events observed in the study were related to TDF toxicity. Concomitant medications
and other drugs that could affect renal function were not collected. Therefore, our results
should be interpreted with care.
Conclusion
In conclusion, 4.2% of individuals on TDF—containing ART experienced renal dysfunction
defined as eGFR decline to<60ml/min/1.73m2 with>30% reduction from baseline and age
older than 50 years, pre-TDF eGFR<60 ml/min/1.73m2 and PI-based regimen were at greater
risk. These data suggest potential benefits in these higher risk groups for renal function moni-
toring during TDF-containing ART in resource-limited settings. Further studies are needed to
assess the optimal interval of renal function monitoring during TDF use.
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board
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